Q2 2025 Management View Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Given this risk, we thought we'd take a look at whether Skye Bioscience (NASDAQ:SKYE) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate ...

Skye Bioscience’s nimacimab blocks CB1, the same receptor targeted by an obesity drug candidate now in the hands of Novo Nordisk. But Skye contends its Phase 2-ready antibody drug has several ...

Skye Bioscience, Inc., a biotechnology company specializing in treatments for obesity and metabolic disorders, announced the launch of its "Anatomy of Progress" video series, showcasing the ...

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Mar. 20, 2025 4:01 PM ET Skye Bioscience, Inc. (SKYE) ...

About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors.

Skye preparing to start Phase 2a glaucoma clinical trial in Q3San Diego, California-- (Newsfile Corp. - July 13, 2023) - Skye Bioscience, Inc. (OTC ...

About Skye Bioscience Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic processes.

Skye Bioscience, Inc. announced that it has granted stock options for 56,000 shares of its common stock to two new non-executive employees as part of its 2024 Inducement Equity Incentive Plan, in ...

Get the latest Skye Bioscience Inc. R (09R.F) stock news and headlines to help you in your trading and investing decisions.

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation ...